Dataset: 11.1K articles from the COVID-19 Open Research Dataset (PMC Open Access subset)
All articles are made available under a Creative Commons or similar license. Specific licensing information for individual articles can be found in the PMC source and CORD-19 metadata
More datasets: Wikipedia | CORD-19

Logo Beuth University of Applied Sciences Berlin

Made by DATEXIS (Data Science and Text-based Information Systems) at Beuth University of Applied Sciences Berlin

Deep Learning Technology: Sebastian Arnold, Betty van Aken, Paul Grundmann, Felix A. Gers and Alexander Löser. Learning Contextualized Document Representations for Healthcare Answer Retrieval. The Web Conference 2020 (WWW'20)

Funded by The Federal Ministry for Economic Affairs and Energy; Grant: 01MD19013D, Smart-MD Project, Digital Technologies

Imprint / Contact

Highlight for Query ‹SARS-CoV-2 medication

The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C


Lassa virus belongs to the family of Arenaviridae which includes other important human pathogens like Machupo virus, Junin virus, Guanarito virus and Sabia virus as well as the prototype of this family, Lymphocytic Choriomeningitis virus (LCMV). Lassa virus is endemic in certain parts of West Africa and causes an estimated 150 000 clinical cases of a systemic viral illness per year, with a mortality rate of 10–15%. Lassa fever is not only a public health concern in endemic areas, it is also sporadically exported to other parts of the world.

Lassa virus is an enveloped virus with a bi-segmented RNA genome which encodes four viral proteins in an ambisense coding strategy: the glycoprotein precursor preGP-C, a nucleoprotein (NP), the viral polymerase L and the matrix protein Z (for review see). The Lassa virus glycoprotein is translated as an inactive precursor (pre-GP-C) into the lumen of the endoplasmic reticulum and is then cotranslationally cleaved into GP-C and a stable signal peptide. The latter one plays an important role in the subsequent posttranslational maturation cleavage of GP-C into its subunits GP1 and GP2. Lassa virus GP-C is cleaved at the C-terminus of a non-basic amino acid residue of the cleavage motif R-R-L-L by the subtilase SKI-1/S1P, which is unusual for fusiogenic glycoproteins of enveloped viruses. So far, only viral glycoproteins of the arenavirus family and the glycoprotein of the Crimean-Congo hemorrhagic fever virus belonging to the family of Bunyaviridae are known to be cleaved by SKI-1/S1P, an enzyme that normally plays a role in regulation of the lipid metabolism of the cell. Fusiogenic glycoproteins of most other enveloped viruses are proteolytically cleaved C-terminally of a single arginine residue or at a multibasic recognition motif by the subtilase furin.

N-glycans play not only an important role in folding and intracellular transport of viral glycoproteins but also are known to modulate their antigenicity and activity. Glycoproteins of arenaviruses vary considerably in number and position of potential N-glycosylation sites as shown by an N-glycosylation prediction program (Table 1). The Lassa virus glycoprotein GP-C contains eleven potential N-glycosylation consensus sites (N-X-S/T, in which X can be any amino acid except proline), where seven of these are located in the GP1- and four in the GP2-subunit (Table 1). Using limited N-Glycanase digestion, Wright et al. demonstrated for LCMV GP that five potential glycosylation sites on GP-1 were utilized and two of the three sites on GP-2. However, for Lassa virus GP it has not yet been shown which sites are actually used and how N-glycosylation affects the characteristics of the glycoprotein in respect to cleavage and transport along the exocytotic pathway. To address this question, we investigated in the present report each potential N-glycosylation site of the Lassa virus glycoprotein concerning N-glycan maturation, cleavage of GP-C and glycoprotein transport to the cell surface. We provide evidence that each of the 11 N-glycosylation sites is used for N-glycan attachment. However, seven N-glycan mutants failed in their ability to get proteolytically processed, while 4 N-glycosylation sites are individually dispensable for cleavage of GP-C. Furthermore, we demonstrate that both uncleaved precursor and cleavage-defective N-glycan mutants are transported to the cell surface and remain mannose-rich.

Cell culture

Vero cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO) supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin, and 0.1 mg/ml streptomycin.


Oligopeptide comprising the amino acids 477–491 of preGP-C was chemically synthesized and covalently linked to keyhole limpet hemocyanin (KLH, Pierce) as a carrier protein by the cross-linker agent N- [α-maleimidoacetoxy] succinimide ester (AMAS) and used for repeated immunization of rabbits as described before. The obtained antiserum Rb-α-GP2 was tested by peptide standard ELISA and used for immunoblot analyses.

Mutation and vectorial expression of recombinant Lassa virus glycoprotein

The full length glycoprotein of Lassa virus (strain Josiah) was expressed using the beta-actin promotor-driven pCAGGS vector. Lassa virus N-glycosylation mutants were generated by recombinant PCR using overlapping oligonucleotides, which will be made available on request. Sequences of mutants were confirmed by DNA sequencing. Vero cells were transfected with wild type and mutated recombinant DNA using Lipofectamine 2000 (Gibco/Invitrogen).

Cell surface biotinylation assay, immunoprecipitation and treatment with glycosidases

Wild type glycoprotein of Lassa virus or N-glycosylation mutants were expressed in Vero cells. At 24 h post-transfection, cells were washed three times with cold phosphate-buffered saline (PBS) and then cell surface was incubated twice for 15 min at 4°C with 2 mg/ml sulfo-N-hydroxysuccinimidobiotin (Pierce) by adding 1 ml of the biotinylating reagent. After biotinylation, cells were washed twice with cold PBS containing 0.1 M glycine and three times with PBS. Cells were lysed in 0.5 ml RIPA (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 10 mM EDTA, 10 mM iodacetamide, 1 mM phenylmethylsulfonyl fluoride, 50 units/ml aprotinin, and 20 mM Tris-HCl), followed by centrifugation for 30 min at 20 000 g. The supernatant was immunoprecipitated with anti-GP-C at a final dilution of 1:1000. After addition of 30 μl protein A-Sepharose CL-4B (Sigma), immunocomplexes were washed three times with RIPA. Then samples were treated with either endo-β-N-acetylglucosaminidase H (endo H; New England Biolabs) or N-glycosidase F (PNGase F; New England Biolabs) according to the instructions of the manufacturer, or left untreated. Samples were resuspended in reducing sample buffer for SDS-polyacrylamide gel electrophoresis (PAGE), followed by separation on a 12% polyacrylamide gel, before proteins were blotted to nitrocellulose. Biotinylated cell surface proteins were detected by incubation with a streptavidin-biotinylated horseradish peroxidase complex (Amersham Pharmacia Biotech) diluted 1:2000 in PBS. Proteins were visualized with the enhanced chemiluminescence system (Amersham Pharmacia Biotech) by exposure to an autoradiography film (Kodak BIOMAX).

Mutation of potential N-glycosylation sites of Lassa virus preGP-C

Lassa virus preGP-C contains 11 potential N-glycosylation sites, 7 in the GP-1- and 4 in the GP-2-subunit (Fig. 1). To investigate whether each N-glycosylation site is used for N-glycan attachment, the corresponding serine or threonine residues of potential N-glycosylation motifs (N-X-S/T) were individually changed to alanine. GP-1 mutants were designated T81A, S91A, T101A, S111A, S121A, S169A and T226A and GP-2 mutants S367A, S375A, S392A and S397A. All cDNA constructs were expressed transiently in Vero cells using the beta-actin promoter-driven mammalian expression vector pCAGGS. Western blotting was performed using antiserum directed against the C-terminus of GP-2. As shown in Fig. 2A (lanes 2–8, upper panel) and Fig. 2B (lanes 2–5, upper panel), all mutants showed faster migration on a SDS gel compared to wild-type GP-C indicating that each N-glycosylation site is used for N-glycan attachment. Next we determined the effect of the individual N-glycans on the maturation cleavage by analysing the presence of the cleaved subunit GP-2. Disruption of the N-glycosylation sites within the GP-1 mutants S111A, S169A and T226A has no influence on GP-C cleavage (Fig. 2A, lanes 5, 7 and 8, lower panel). In contrast, the lack of N-glycan attachment of the GP-1 mutants T81A, S91A, S101A and S121A abolished the proteolytical processing by SKI-1/S1P (Fig. 2A, lanes 2–4 and 6, lower panel). Among the four N-glycosylation sites of GP-2, only GP-C of the mutants S392A and S397A are further cleaved into GP-1 and GP-2 similar to fully glycosylated wild-type GP-C (Fig. 2B, lanes 4 and 5, lower panel), whereas no cleavage of the glycoprotein was observed within the mutants S367A and S375A (Fig. 2B, lanes 2 and 3, lower panel). Due to the high resolution of the acrylamid gel electrophoresis, the GP-2 subunit of mutants S392A and S397A revealed significantly faster electrophoretic mobility than wild type GP-2 (Fig. 2B; lanes 4–5, lower panel) showing that the respective N-glycosylation sites are used for N-glycan attachment.

Cell surface transport of GP N-glycosylation mutants

N-glycosylation has long been known to be essential for correct folding and intracellular transport of viral glycoproteins, as shown for instances for influenza hemagglutinin. In order to investigate the importance of the individual N-glycosylation sites of Lassa virus GP-C for intracellular trafficking we analysed cell surface expression of the mutated glycoproteins using a biotinylation approach. Transfected Vero cells were labelled with non-membrane-permeating biotin as described in material and methods. After biotinylation, cells were lysed and GP-C and GP-C N-glycan mutants were immunoprecipitated using polyclonal antiserum directed against the C-terminus of GP-C. The precipitates were separated on an SDS gel and transferred to nitrocellulose. Surface-expressed glycoprotein protein was then visualised with a streptavidin-peroxidase complex. Fig. 3A (lanes 2–8) and B (lanes 2–5) demonstrate that all GP-1 and GP-2 N-glycosylation mutants are transported to the cell surface in a similar manner compared to wild-type GP indicating that a loss of a single N-glycosylation attachment site and proteolytic cleavage are not necessary for cell surface transport of GP. For LCMV it was shown that maturation cleavage deficient mutants are efficiently transported to the cell surface. Both cleavage and cell surface expression of LCMV GP-C are impaired in parallel either when no N-glycosylation occurs or a proline residue is present at position 110. Since many cleavage deficient mutants have been shown to exhibit regular cell surface transport, the two reported cases in which cell surface expression was abolished might be due to misfolding in the endoplasmic reticulum with subsequent degradation.

Transport of endo H-sensitive GP-C to the cell surface

LCMV and Lassa virus GP-C are cleaved by the same protease, SKI-1/S1P, although proteolytic processing of the GPs occurs in different subcellular compartments. Lassa virus GP-C is cleaved early along the secretory pathway in the ER or an early Golgi stack, whereas LCMV GP-C is cleaved in the Golgi or post-Golgi compartment. Furthermore, for LCMV GP-C it has been shown that transition of mannose-rich carbohydrates to complex carbohydrates occurred before maturation cleavage. In order to analyse the glycosylation status of Lassa virus glycoproteins on the outer cell membrane, cell surface biotinylation was combined with a subsequent detachment of mannose-rich N-glycans by digestion with endo H or removal of complex N-glycans using PNGase F (Fig. 4). The GP-2 subunit is detectable at the cell surface and displays partial endo H-resistance confirming a modification of its carbohydrate decoration during glycoprotein transport to the cell surface (lane 2). Interestingly, the glycoprotein precursor GP-C which is transported to the cell surface remains completely endo H-sensitive suggesting that cleavage might be a prerequisite for further complex glycosylation. In addition, uncleaved endo H-sensitive Lassa virus GP-C is also transported to the cell surface of SKI-1/S1P deficient cells (data not shown).

The finding that only an endo H-sensitive form of Lassa virus GP-C was found at the cell surface suggests that partial endo H-resistance of the Lassa virus glycoprotein is only acquired when the glycoprotein is cleaved into its subunits. This observation is in contrast to findings for the LCMV glycoprotein where an endo H-resistant form of GP-C was described. However, since cleavage of Lassa virus GP-C by SKI-1/S1P occurs earlier in the exocytotic pathway than LCMV GP-C, cleavage of Lassa virus GP-C occurs prior to trimming of the mannose-rich N-glycans to complex sugar types.

It can not be ruled out that the use of glycosylation sites and the N-glycan trimming differs between recombinant expressed glycoproteins and GP in LASV-infected cells. It was shown recently that recombinant expressed M protein of SARS-CoV gained complex-type N-glycosylation whereas in SARS-CoV infected cells N-glycosylation of M remained endo H-sensitive. However, in general a good correlation between results obtained after solitary expression and studies using the homologues viral system have been observed. To address this kind of issues, the development of a "reverse genetic system" for LASV will be necessary that would allow analysing the role of glycosylation of GP in the correct viral context.


Taken together, our study suggest that individual N-linked oligosaccharides of the Lassa virus glycoprotein differ greatly in terms of their importance for correct protein folding which seems to be important for activation cleavage by SKI-1/S1P. The differences between the precursor glycoprotein GP-C and the cleaved subunits GP-1 and GP-2, not only with respect to N-glycosylation, remain an enigma since only the cleaved glycoprotein subunits are incorporated into virus particles.


aa; amino acid; DMEM, Dulbecco's Modified Eagle's Medium; GP, glycoprotein, PCR, polymerase chain reaction; Endo H, endoglycosidase H; PNGase F, peptide-N-glycosidase F; RIPA, radio immunoprecipitation assay; SKI-1/S1P, subtilisin kexin isoenzyme-1/site 1 protease; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; Tris, tris-(hydroxymethyl)-aminomethan.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

RE and TS carried out experiments, participated in the analysis of the results and drafted the manuscript. OL helped to draft the manuscript and revised it critically. WG designed the study, participated in the analysis of the results and helped to draft the manuscript. All authors read and approved the final manuscript.